Cargando...
The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas
Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat(®), Temodal(®) or Temodar(®)) is a first-line treatment for malignant gliomas but the development of drug resistance remains a major concern. Activating transcription factor 4 (ATF4) is a c...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584239/ https://ncbi.nlm.nih.gov/pubmed/28881638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17737 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|